Bone Biologics Corp. (NASDAQ:BBLG) Short Interest Update

Bone Biologics Corp. (NASDAQ:BBLG) was the recipient of a large increase in short interest during the month of August. As of August 14th, there was short interest totaling 156,590 shares, an increase of 646.3% from the July 30th total of 20,981 shares. Based on an average daily volume of 1,559,990 shares, the short-interest ratio is currently 0.1 days. Approximately 6.0% of the shares of the company are short sold.

Bone Biologics Trading Down 0.5%

BBLG stock opened at $0.60 on Wednesday. The firm’s 50-day moving average is $1.09 and its two-hundred day moving average is $1.20. The company has a market capitalization of $1.67 million, a price-to-earnings ratio of -0.44 and a beta of 0.92. Bone Biologics has a 52 week low of $0.58 and a 52 week high of $4.13.

Bone Biologics (NASDAQ:BBLG) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.04). On average, equities research analysts predict that Bone Biologics will post -1.23 earnings per share for the current year.

Hedge Funds Weigh In On Bone Biologics

An institutional investor recently raised its position in Bone Biologics stock. DRW Securities LLC increased its position in Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,576 shares of the company’s stock after buying an additional 12,549 shares during the quarter. DRW Securities LLC owned about 1.31% of Bone Biologics worth $34,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 34.30% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bone Biologics in a report on Friday, July 24th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

About Bone Biologics

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.